Cargando…
A case of CD74‐ROS1‐positive lung adenocarcinoma diagnosed by next‐generation sequencing achieved long‐term survival with pemetrexed regimens
Previously, cytotoxic drugs were the only option for patients with non‐small cell lung cancer (NSCLC) and the prognosis was poor. However, molecularly targeted therapies and immune checkpoint inhibitors represent a breakthrough in the treatment of advanced NSCLC and have improved survival rates. In...
Autores principales: | Tanaka, Satoshi, Yoshimura, Nobuaki, Asakawa, Ryo, Tobita, Satoshi, Yaga, Moto, Ueno, Kiyonobu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481135/ https://www.ncbi.nlm.nih.gov/pubmed/37488715 http://dx.doi.org/10.1111/1759-7714.15041 |
Ejemplares similares
-
Bilateral refractory pneumothorax treated by pleurodesis and bronchial occlusion in a COVID‐19 patient
por: Tanaka, Satoshi, et al.
Publicado: (2022) -
A case of simultaneous occurrence of hepatitis and pancreatitis during the combination immunochemotherapy for non-small cell lung carcinoma
por: Tanaka, Satoshi, et al.
Publicado: (2020) -
Chemotherapy in Metastatic NSCLC – New Regimens (Pemetrexed, Nab-Paclitaxel)
por: Blais, Normand, et al.
Publicado: (2014) -
Memorandum: next meeting-74-59
por: Buude, R
Publicado: (1974) -
Memorandum: next meeting-74-66
por: Buude, R
Publicado: (1974)